Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 6.38B +720.4% |
| Revenue (ttm) | 324.97M +34.5% |
| Net Income | -289.52M |
| EPS | -0.71 |
| Shares Out | 452.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,760,272 |
| Open | 14.19 |
| Previous Close | 14.14 |
| Day's Range | 13.54 - 14.30 |
| 52-Week Range | 1.76 - 15.37 |
| Beta | 0.76 |
| Analysts | Buy |
| Price Target | 14.40 (+2.2%) |
| Est. Earnings | Nov 5, 2026 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w... [Read more]
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $14.4, which is an increase of 2.20% from the latest price.
News
Iovance’s Amtagvi shows durability in 1L melanoma, says Jefferies
Updated Phase II data from Iovance (IOVA) for Amtagvi plus PD-1 in first-line melanoma showed durable PFS competitive with approved combinations, supporting the ongoing Phase III TILVANCE-301 and pote...
Iovance says one-time lifileucel showed 29.2% complete response rate
Iovance (IOVA) announced that one-time lifileucel combined with pembrolizumab demonstrated a 62.5% objective response rate and a 29.2% complete response rate, with median overall survival not reached ...
Iovance drops 3% to $13.67 after new melanoma data
10:23 EDT Iovance (IOVA) drops 3% to $13.67 after new melanoma data
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Pre...
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Trea...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering nov...
Iovance Biotherapeutics price target raised to $18 from $15 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $18 from $15 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Iovance Biotherapeutics price target raised to $11 from $6 at Baird
Baird raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $11 from $6 and keeps a Neutral rating on the shares. The firm updated its model following its updated…
Iovance Biotherapeutics appoints Berkowitz as CMO
Iovance Biotherapeutics (IOVA) announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, CMO, effective September 30, 2026. Berkowitz previously served as Senior Vice Preside...
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innova...
Iovance Biotherapeutics price target raised to $18 from $14 at Wells Fargo
Wells Fargo raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $18 from $14 and keeps an Overweight rating on the shares. Following the updated guidance and management discussion,…
Iovance Biotherapeutics rises 27.8%
Iovance Biotherapeutics (IOVA) is up 27.8%, or $3.06 to $14.05.
Iovance Biotherapeutics price target raised to $20 from $9 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $20 from $9 and keeps a Buy rating on the shares after the company raised…
Iovance Biotherapeutics rises 25.9%
Iovance Biotherapeutics (IOVA) is up 25.9%, or $2.85 to $13.84.
Iovance Biotherapeutics raises FY26 revenue view to $410M-$420M
From $350M-$370M, consensus $402.8M. “Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at…
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept...
Iovance Biotherapeutics resumed with a Buy at Goldman Sachs
Goldman Sachs resumed coverage of Iovance Biotherapeutics (IOVA) with a Buy rating and $15 price target The firm sees an inflection in the company’s Amtagvi launch. The logistical and operational…
Iovance Biotherapeutics put buyer realizes 64% same-day gains
Notable profits for the buyer who lifted the $1.10 offer for 1,867 Iovance Biotherapeutics (IOVA) 10/2 weekly 11.5 puts yesterday at 11:00ET when underlying shares were trading at $10.90. Shares…
Iovance Biotherapeutics price target raised to $15 from $13 at Barclays
Barclays raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $15 from $13 and keeps an Overweight rating on the shares. The firm’s physician survey reinforce its positive outlook…
Iovance Biotherapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Record quarterly revenue, expanding margins, and a robust cash position support ongoing growth in TIL therapy. Clinical data show unprecedented response and durability in melanoma, with pipeline advances in lung, sarcoma, and endometrial cancers, plus next-gen therapies in development.
Iovance Biotherapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
AMTAGVI sales and treatment center expansion are driving strong growth, with positive demand trends and margin improvements expected to continue. The pipeline advances with key lung and melanoma trials, while next-generation TIL therapies and international expansion offer further opportunities.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in...
Iovance Biotherapeutics put volume heavy and directionally bearish
Bearish flow noted in Iovance Biotherapeutics (IOVA) with 2,610 puts trading, or 1.4x expected. Most active are 9/4 weekly 8 puts and Sep-26 10 calls, with total volume in those…
Iovance Biotherapeutics Earnings Call Transcript: Q2 2026
Record Q2 revenue and margin were driven by robust Amtagvi demand, expanding ATC network, and operational efficiencies. Pipeline advanced with key regulatory milestones and international approvals, while strong cash reserves support ongoing growth and R&D.
Iovance Biotherapeutics Earnings release: Q2 2026
Iovance Biotherapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.